NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.
Archive | Of Interest
NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers
Posted in Melanoma News, Health Professionals, Of Interest
Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma
For about half of patients with advanced melanoma, there is only one treatment choice: immunotherapy. But for those whose late-stage melanoma expresses a BRAF gene mutation, there’s another option – combinations of targeted drugs.
Posted in Melanoma News, Health Professionals, Of Interest
Novel nano-vaccine for melanoma
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer.
Posted in Melanoma News, Health Professionals, Of Interest
Melanoma Checkpoint Therapy More Potent in Combination with Nanovaccine
Dissonant signaling, which can deafen the immune system to cancer, can be replaced by something more harmonious—and therapeutic—if immunotherapies silence a note, sound another, or play an especially resonant chord.
Posted in Melanoma News, Health Professionals, Of Interest
